Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
20 10 2019
Historique:
pubmed: 30 8 2019
medline: 11 6 2020
entrez: 30 8 2019
Statut: ppublish

Résumé

Seasonal influenza vaccination is recommended for patients with cancer despite concerns of disease or treatment-associated immunosuppression. The objective of this study was to evaluate vaccine effectiveness (VE) against laboratory-confirmed influenza for patients with cancer. We conducted an observational test-negative design study of previously diagnosed patients with cancer 18 years of age and older who underwent influenza testing during the 2010-2011 to 2015-2016 influenza seasons in Ontario, Canada. We linked individual-level cancer registry, respiratory virus testing, and health administrative data to identify the study population and outcomes. Vaccination status was determined from physician and pharmacist billing claims. We used multivariable logistic regression to estimate VE, adjusting for age, sex, rurality, income quintile, cancer characteristics, chemotherapy exposure, comorbidities, previous health care use, influenza season, and calendar time. We identified 26,463 patients with cancer who underwent influenza testing, with 4,320 test-positive cases (16%) and 11,783 (45%) vaccinated. Mean age was 70 years, 52% were male, mean time since diagnosis was 6 years, 69% had solid tumor malignancies, and 23% received active chemotherapy. VE against laboratory-confirmed influenza was 21% (95% CI, 15% to 26%), and VE against laboratory-confirmed influenza hospitalization was 20% (95% CI, 13% to 26%). For patients with solid tumor malignancies, VE was 25% (95% CI, 18% to 31%), compared with 8% (95% CI, -5% to 19%) for patients with hematologic malignancies ( Our results support recommendations for influenza vaccination for patients with cancer. VE was decreased for patients with hematologic malignancies, and there was no significant difference in VE among patients with solid tumor cancer receiving active chemotherapy. Strategies to optimize influenza prevention among patients with cancer are warranted.

Identifiants

pubmed: 31465264
doi: 10.1200/JCO.19.00354
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2795-2804

Subventions

Organisme : CIHR
ID : MOP 130568
Pays : Canada

Auteurs

Phillip S Blanchette (PS)

University of Western Ontario, London, Ontario, Canada.
London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada.
ICES London and Toronto, Ontario, Canada.

Hannah Chung (H)

ICES London and Toronto, Ontario, Canada.

Kathleen I Pritchard (KI)

Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.

Craig C Earle (CC)

ICES London and Toronto, Ontario, Canada.
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.

Michael A Campitelli (MA)

ICES London and Toronto, Ontario, Canada.

Sarah A Buchan (SA)

ICES London and Toronto, Ontario, Canada.
Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.

Kevin L Schwartz (KL)

ICES London and Toronto, Ontario, Canada.
Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.

Natasha S Crowcroft (NS)

ICES London and Toronto, Ontario, Canada.
Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.

Jonathan B Gubbay (JB)

Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.
The Hospital for Sick Children, Toronto, Ontario, Canada.

Timothy Karnauchow (T)

Children Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
University of Ottawa, Ottawa, Ontario, Canada.

Kevin Katz (K)

University of Toronto, Toronto, Ontario, Canada.
North York General Hospital, Toronto, Ontario, Canada.

Allison J McGeer (AJ)

University of Toronto, Toronto, Ontario, Canada.
Mount Sinai Hospital, Ontario, Canada.

James D McNally (JD)

Children Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

David C Richardson (DC)

William Osler Health System, Brampton, Ontario, Canada.

Susan E Richardson (SE)

University of Toronto, Toronto, Ontario, Canada.
The Hospital for Sick Children, Toronto, Ontario, Canada.

Laura C Rosella (LC)

ICES London and Toronto, Ontario, Canada.
Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.

Andrew Simor (A)

University of Toronto, Toronto, Ontario, Canada.
Sunnybrook Health Science Centre, Toronto, Ontario, Canada.

Marek Smieja (M)

McMaster University, Hamilton, Ontario, Canada.

George Zahariadis (G)

Memorial University, St. John's, Newfoundland and Labrador, Canada.

Aaron Campigotto (A)

University of Toronto, Toronto, Ontario, Canada.
The Hospital for Sick Children, Toronto, Ontario, Canada.

Jeffrey C Kwong (JC)

ICES London and Toronto, Ontario, Canada.
Public Health Ontario, Toronto, Ontario, Canada.
University of Toronto, Toronto, Ontario, Canada.
University Health Network, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH